SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study
Portfolio Pulse from
Sage Therapeutics' phase II DIMENSION study on dalzanemdor for Huntington's disease did not meet its primary goal, marking another setback in their pipeline.
November 21, 2024 | 5:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sage Therapeutics' phase II study on dalzanemdor for Huntington's disease failed to meet its primary goal, indicating a setback in their drug development pipeline.
The failure of the phase II study is a significant setback for Sage Therapeutics as it impacts their drug development pipeline. This news is likely to negatively affect investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100